251 related articles for article (PubMed ID: 33506984)
1. Recalcitrant chronic urticaria treated with dupilumab: Report of two instances refractory to H1-antihistamines, omalizumab and cyclosporine and brief literature review.
Errichetti E; Stinco G
Dermatol Ther; 2021 Mar; 34(2):e14821. PubMed ID: 33506984
[No Abstract] [Full Text] [Related]
2. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Maurer M; Casale TB; Saini SS; Ben-Shoshan M; Giménez-Arnau AM; Bernstein JA; Yagami A; Stjepanovic A; Radin A; Staudinger HW; Patel N; Amin N; Akinlade B; Fan C; Bauer D; Yancopoulos GD; Patel K; Mannent LP; Laws E
J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
[TBL] [Abstract][Full Text] [Related]
3. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
Holm JG; Sørensen JA; Thomsen SF
Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
[No Abstract] [Full Text] [Related]
4. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
[No Abstract] [Full Text] [Related]
5. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
[No Abstract] [Full Text] [Related]
6. Chronic Urticaria.
Hsu JI; Hsu S
Skinmed; 2022; 20(5):364-366. PubMed ID: 36314703
[TBL] [Abstract][Full Text] [Related]
7. Chronic Urticaria.
Hsu JI; Hsu S
Skinmed; 2022; 20(4):364-366. PubMed ID: 36314621
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
[TBL] [Abstract][Full Text] [Related]
10. New treatments for chronic urticaria.
Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
[TBL] [Abstract][Full Text] [Related]
12. Current and future management of chronic spontaneous urticaria and chronic inducible urticaria.
Do TT; Canty EA; Joshi SR
Allergy Asthma Proc; 2023 Jan; 44(1):3-14. PubMed ID: 36719690
[No Abstract] [Full Text] [Related]
13. Cyclosporine and omalizumab together: A new option for chronic refractory urticaria.
Sánchez J; Alvarez L; Cardona R
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2101-2103. PubMed ID: 32112923
[No Abstract] [Full Text] [Related]
14. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
Garbayo-Salmons P; Expósito-Serrano V
Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
[No Abstract] [Full Text] [Related]
15. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
[No Abstract] [Full Text] [Related]
16. Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria.
Giménez Arnau AM; Valero Santiago A; Bartra Tomás J; Jáuregui Presa I; Labrador Horrillo M; Miquel Miquel FJ; Ortiz de Frutos J; Sastre J; Silvestre Salvador JF; Ferrer Puga M
J Investig Allergol Clin Immunol; 2019; 29(5):338-348. PubMed ID: 30222111
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
18. The use of omalizumab for treatment-refractory chronic spontaneous urticaria in a West Australian outpatient cohort.
Farrah G; Stevenson B; Lie K; Brusch A
Intern Med J; 2019 Apr; 49(4):526-528. PubMed ID: 30957371
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence.
Tonacci A; Nettis E; Asero R; Rossi O; Tontini C; Gangemi S
Eur Ann Allergy Clin Immunol; 2020 May; 52(3):100-103. PubMed ID: 32108461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
